No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EXAS240816C52500
- 1.85
- +0.30+19.35%
15min DelayClose Jul 22 16:00 ET
1.95High1.60Low
1.60Open1.55Pre Close116 Volume113 Open Interest52.50Strike Price21.64KTurnover68.42%IV12.84%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry1.85Extrinsic Value100Contract SizeAmericanOptions Type0.3561Delta0.0430Gamma25.35Leverage Ratio-0.0666Theta0.0106Rho9.03Eff Leverage0.0472Vega
Intraday
- 5D
- Daily
News
Piper Sandler Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $80
Piper Sandler analyst David Westenberg maintains $Exact Sciences(EXAS.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 45.5%
Exact Sciences (EXAS) Receives a Buy From Piper Sandler
Express News | Exact Sciences Corp : Bernstein Raises Target Price to $83 From $81
Peeling Back The Layers: Exploring Exact Sciences Through Analyst Insights
Analysts' ratings for Exact Sciences (NASDAQ:EXAS) over the last quarter vary from bullish to bearish, as provided by 8 analysts.In the table below, you'll find a summary of their recent ratings,
Exact Sciences Is Maintained at Buy by Goldman Sachs
Exact Sciences Is Maintained at Buy by Goldman
Express News | Goldman Sachs Maintains Buy on Exact Sciences, Lowers Price Target to $75
Comments
$Exact Sciences(EXAS.US$ guys relax sooner or later this will grow just not so soon
1
1
$Exact Sciences(EXAS.US$ whats happening? why it keeps dropping?
$Exact Sciences(EXAS.US$ Good opportunity to buy after correction, "not today" I shall buy in next week once volatility minimized. Good AI stoks but you can see good return not before 2025. I am bullish on it and it will remain my best pick for next 3-5 years invetment tenure.
2
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
Read more
Baboompiak : yup holding onto 100 shares at 57.5